FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Baird Remains Bullish on Alexion Pharma (ALXN) as FDA Approves Strensiq
October 27, 2015 9:14 AM EDTBaird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ET
October 23, 2015 3:57 PM EDTAlexion Pharma (NASDAQ: ALXN) to Resume Trading at 4:15 PM ET
... MoreFDA Approves Alexion's (ALXN) Strensiq to Treat Perinatal, Infantile and Juvenile-Onset HPP
October 23, 2015 3:40 PM EDT(Updated - October 23, 2015 3:45 PM EDT)
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
HPP is a rare, genetic, progressive, metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to severe disability and life-threatening complications. It is characterized by defective bone mineralization that can lead to rickets and softening of the bones that result in skeletal abnormalities. It can also cause complications such as profound muscle weakness with loss of mobility, seizures, pain, respiratory failure and... More
Alexion Pharma (ALXN) halted with news pending
October 23, 2015 3:38 PM EDTAlexion Pharma (NASDAQ: ALXN) trading halted with news pending.
... More